Literature DB >> 20011560

Accomplishments in 2008 in the adjuvant treatment of colon cancer.

John L Marshall1, Aimery de Gramont, Claus-Henning Köhne, J L Marshall, A de Gramont, C-H Köhne.   

Abstract

Overview of the Disease IncidencePrognosisCurrent General Therapy Standards StagingLymph Node ExcisionStage III DiseaseStage II DiseaseMolecular MarkersAccomplishments During the Year Therapy Cytotoxic ChemotherapyChemotherapy Plus Targeted TherapySpecial PopulationsBasic Science-BiomarkersMethodologyWhat Needs to Be Done Application of the AccomplishmentsControversies and DisagreementsFuture Directions Comments on ResearchObstacles to Progress.

Entities:  

Year:  2009        PMID： 20011560      PMCID： PMC2791381     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


  14 in total

Review 1.  Lymph node evaluation and survival after curative resection of colon cancer: systematic review.

Authors:  George J Chang; Miguel A Rodriguez-Bigas; John M Skibber; Virginia A Moyer
Journal:  J Natl Cancer Inst       Date:  2007-03-21       Impact factor: 13.506

2.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

Authors:  Daniel G Haller; Paul J Catalano; John S Macdonald; Mark A O'Rourke; Michael S Frontiera; Don V Jackson; Robert J Mayer
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

3.  A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

Authors:  I Chau; A R Norman; D Cunningham; D Tait; P J Ross; T Iveson; M Hill; T Hickish; F Lofts; D Jodrell; A Webb; J R Oates
Journal:  Ann Oncol       Date:  2005-02-02       Impact factor: 32.976

4.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

5.  Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.

Authors:  J Philip Kuebler; H Samuel Wieand; Michael J O'Connell; Roy E Smith; Linda H Colangelo; Greg Yothers; Nicholas J Petrelli; Michael P Findlay; Thomas E Seay; James N Atkins; John L Zapas; J Wendall Goodwin; Louis Fehrenbacher; Ramesh K Ramanathan; Barbara A Conley; Patrick J Flynn; Gamini Soori; Lauren K Colman; Edward A Levine; Keith S Lanier; Norman Wolmark
Journal:  J Clin Oncol       Date:  2007-04-30       Impact factor: 44.544

6.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

7.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Authors:  Christine M Ribic; Daniel J Sargent; Malcolm J Moore; Stephen N Thibodeau; Amy J French; Richard M Goldberg; Stanley R Hamilton; Pierre Laurent-Puig; Robert Gryfe; Lois E Shepherd; Dongsheng Tu; Mark Redston; Steven Gallinger
Journal:  N Engl J Med       Date:  2003-07-17       Impact factor: 91.245

8.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.

Authors:  Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

9.  Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.

Authors:  Thierry André; Emmanuel Quinaux; Christophe Louvet; Philippe Colin; Erik Gamelin; Olivier Bouche; Emmanuel Achille; Pascal Piedbois; Nicole Tubiana-Mathieu; Arnaud Boutan-Laroze; Michel Flesch; Gérard Lledo; Yves Raoul; Isabelle Debrix; Marc Buyse; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

10.  Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.

Authors:  Carmen J Allegra; Greg Yothers; Michael J O'Connell; Saima Sharif; Linda H Colangelo; Samia H Lopa; Nicholas J Petrelli; Richard M Goldberg; James N Atkins; Thomas E Seay; Louis Fehrenbacher; Seamus O'Reilly; Luis Chu; Catherine A Azar; Norman Wolmark
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544
View more
  1 in total

1.  Comparative Effectiveness of Oxaliplatin Versus 5-flourouricil in Older Adults: An Instrumental Variable Analysis.

Authors:  Christina DeFilippo Mack; M Alan Brookhart; Robert J Glynn; Anne Marie Meyer; William R Carpenter; Robert S Sandler; Til Stürmer
Journal:  Epidemiology       Date:  2015-09       Impact factor: 4.822
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.